HCC

IV Sintilimab and Bevacizumab Biosimilar Improve Survival in Frontline Advanced HCC

September 28, 2020

The sintilimab injection in combination with IBI305, a biosimilar to bevacizumab, improved overall survival as well as progression-free survival compared with sorafenib as front-line treatment of patients with advanced hepatocellular carcinoma, meeting the predefined primary end point of the phase 3 ORIENT-32 clinical trial.

Survival Improved With HAIC Over Standard TACE in Unresectable HCC

September 20, 2020

A significant improvement in overall survival was observed with the addition of hepatic arterial infusion chemotherapy to oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.